Dermatology News

Prevalence of prurigo nodularis is higher than previously estimated and is associated with many comorbidities, according to a study.

Brepocitinib, in doses of either 30 mg or 60 mg, is superior to placebo in reducing signs and symptoms of psoriatic arthritis and is “generally well tolerated” through 52 weeks, according to data published in Arthritis & Rheumatology.

In this edition, novel serum improves hair growth in androgenetic alopecia; cardiovascular disease linked to dermatological inflammatory diseases; sugary drinks may be associated with male pattern hair loss and more.

Patients with autoimmune diseases or long COVID who used a personalized digital care program alongside other non-pharmacologic strategies were more likely to achieve better health-related quality of life scores, according to data.

As age and body weight increased among secukinumab-treated pediatric patients with chronic plaque psoriasis, so did the incidence rate of adverse events, according to pooled safety data from two phase 3 studies.

Secukinumab and adalimumab demonstrate similar efficacy regarding the resolution of enthesitis over 52 weeks in patients with psoriatic arthritis, according to data published in Rheumatology.

Skin self-examination is a viable secondary prevention method for the early detection of metastatic melanoma and should be promoted to patients, according to an article published in the Journal of the American Academy of Dermatology.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.

In a panel-led project, 23 experts created a comprehensive guide for the long-term management of inflammatory skin diseases in pediatric patients treated with methotrexate.

Johnson & Johnson has settled its lawsuit with Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States, according to results of a federal court filing.